Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Celator(R) Pharmaceuticals Selected to Participate in NCI's Nanotechnology Characterization Laboratory Assay Cascade for Characterization of Nanoparticle Prodrug Delivery Platform

Abstract:
Celator Pharmaceuticals today announced that the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL), operated by SAIC-Frederick (Frederick, Maryland), has agreed to conduct characterization studies to advance the development of the company's nanoparticle drug formulation technology.

Celator(R) Pharmaceuticals Selected to Participate in NCI's Nanotechnology Characterization Laboratory Assay Cascade for Characterization of Nanoparticle Prodrug Delivery Platform

Princeton, NJ | Posted on February 17th, 2010

The agreement is part of the NCI's Advanced Technology Partnerships Initiative, which aims to accelerate the delivery of new products to cancer patients through the strategic application of advanced technologies and effective translational research partnerships.

The current material transfer agreement focuses on Celator's hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation to support an eventual investigational new drug (IND) filing with the U.S. Food and Drug Administration. Specifically, the NCL has selected HDPN for intensive physical characterization, in-vitro studies, and in-vivo pharmacology and toxicology protocols.

HDPN is the result of collaboration with Princeton University and subsequent discovery and research efforts at Celator. The technology belongs to a proprietary nanoparticle prodrug delivery platform with broad potential applicability in cancer and other diseases. Docetaxel is a type of taxane drug that is widely used to treat a range of cancers including lung, breast, and prostate.

Celator scientists have demonstrated the HDPN formulation substantially increases drug circulation lifetime and efficacy compared to conventional docetaxel formulations. These improvements formed the basis of the decision made by the NCL's scientific review committee for the characterization study of HDPN.

"Our approach to delivering taxanes such as docetaxel differs from most in that we make the drug more hydrophobic thereby allowing the nanoparticle-incorporated prodrug to circulate in the blood for days after injection," said Dr. Lawrence Mayer, president and head of research of Celator Pharmaceuticals. "Our studies have shown that keeping the drug circulating for extended times correlates with the ability to induce regression of solid tumors to below detectable limits."

"We are pleased the NCL is conducting this work to help us advance HDPN toward the clinic," said Scott Jackson, chief executive officer of Celator Pharmaceuticals. "The technology has broad potential application in addressing therapeutic needs and HDPN represents our first approach."

####

About Celator Pharmaceuticals
Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two Phase 2 products; CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; a preclinical stage compound, CPX-571 (a liposomal formulation of irinotecan:cisplatin); and multiple research programs, including the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation. Based on the applications of CombiPlex and the proprietary nanoparticle prodrug delivery platform, Celator is positioned to advance a broad pipeline of cancer therapies involving both previously approved and novel drug agents.

For more information, please visit the company's website at www.celatorpharma.com.

Information on ongoing trials is available at www.clinicaltrials.gov.

For more information, please click here

Contacts:
Celator Pharmaceuticals, Inc.
303B College Road East
Princeton, NJ 08540
USA
Telephone: (609) 243-0123
Fax: (609) 243-0202

Celator Pharmaceuticals Corp.
1779 West 75th Avenue
Vancouver, BC V6P 6P2
Canada
Telephone: (604) 708-5858
Toll-free: (866) 708-5858
Fax: (604) 708-5883

Copyright © PrNewswire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Searching for a nanotech self-organizing principle May 1st, 2016

Clay nanotube-biopolymer composite scaffolds for tissue engineering May 1st, 2016

Cooling graphene-based film close to pilot-scale production April 30th, 2016

Personal cooling units on the horizon April 29th, 2016

Nanomedicine

Clay nanotube-biopolymer composite scaffolds for tissue engineering May 1st, 2016

Nanoparticles hold promise as double-edged sword against genital herpes April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

Announcements

Clay nanotube-biopolymer composite scaffolds for tissue engineering May 1st, 2016

Cooling graphene-based film close to pilot-scale production April 30th, 2016

Personal cooling units on the horizon April 29th, 2016

Exploring phosphorene, a promising new material April 29th, 2016

Nanobiotechnology

Clay nanotube-biopolymer composite scaffolds for tissue engineering May 1st, 2016

Nanoparticles hold promise as double-edged sword against genital herpes April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

Alliances/Trade associations/Partnerships/Distributorships

Electrically Conductive Graphene Ink Enables Printing of Biosensors April 23rd, 2016

Leti Extends Collaboration with Qualcomm on CoolCubeTM 3D Integration Technology for High-Density, High-Performance ICs: Collaboration Goals Include Building an Ecosystem To Take the Chip-stacking Technology from Design to Fabrication April 13th, 2016

FEI Partners with Five Pharmaceutical Companies, the Medical Research Council and the University of Cambridge to form Cryo-EM Research Consortium April 5th, 2016

Strem Chemicals and SONA Nanotech Sign Distribution Agreement for the World’s First Gold Nanorods Synthesized without CTAB February 24th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic